Matthew Kulke
马修·库尔克
MD, MMSc
Chief of Hematology/Oncology; Professor of Medicine血液/肿瘤科主任；医学教授
👥Biography 个人简介
Dr. Matthew Kulke is a preeminent expert in carcinoid tumors and neuroendocrine malignancies. Formerly at Dana-Farber Cancer Institute, he has led landmark clinical trials on somatostatin analogues and systemic therapies, contributing substantially to NET treatment guidelines and research infrastructure.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Carcinoid Tumor Management
Conducted foundational clinical research on the use of somatostatin analogues including octreotide and lanreotide in controlling carcinoid syndrome and tumor growth in metastatic NET.
NET Clinical Trials Leadership
Served as principal investigator for multiple pivotal trials and led the Dana-Farber NET program for over a decade, training the next generation of NET specialists.
Representative Works 代表性著作
Hepatic artery embolization, chemoembolization, and systemic chemotherapy for the treatment of patients with carcinoid tumors
Cancer (1999)
Early study characterizing liver-directed therapies in carcinoid, informing multidisciplinary treatment approaches still used today.
Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome
Journal of Clinical Oncology (2017)
Key trial supporting FDA approval of telotristat ethyl for refractory carcinoid syndrome diarrhea, expanding symptom management options.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
James Yao
MD Anderson Cancer Center
Emily Bergsland
University of California, San Francisco (UCSF)
Eric Liu
Rocky Mountain Cancer Centers
Marianne Pavel
Charité – Universitätsmedizin Berlin
关注 马修·库尔克 的研究动态
Follow Matthew Kulke's research updates
留下邮箱，当我们发布与 Matthew Kulke（Boston Medical Center / Boston University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment